These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 36063204)
21. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with better prognosis. Wang H; Zhao Q Ann Diagn Pathol; 2012 Oct; 16(5):427. PubMed ID: 22561135 [No Abstract] [Full Text] [Related]
22. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer. Kawai M; Hirono S; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Tanioka K; Yamaue H Surgery; 2019 Jun; 165(6):1151-1160. PubMed ID: 30765142 [TBL] [Abstract][Full Text] [Related]
23. CT Texture Analysis of Ductal Adenocarcinoma Downstaged After Chemotherapy. Ciaravino V; Cardobi N; DE Robertis R; Capelli P; Melisi D; Simionato F; Marchegiani G; Salvia R; D'Onofrio M Anticancer Res; 2018 Aug; 38(8):4889-4895. PubMed ID: 30061265 [TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant Phase II Trial of Chemoradiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer. Thanikachalam K; Damarla V; Seixas T; Dobrosotskaya I; Wollner I; Kwon D; Winters K; Raoufi M; Li J; Siddiqui F; Khan G Am J Clin Oncol; 2020 Jun; 43(6):435-441. PubMed ID: 32251119 [TBL] [Abstract][Full Text] [Related]
25. Improved outcomes for borderline resectable adenocarcinoma of the pancreas after neoadjuvant chemotherapy in a community cancer center. Curto EM; Kaza AG; Sturdevant DA; Tuvin DM; Ganai S; Sticca RP Am J Surg; 2022 Dec; 224(6):1426-1431. PubMed ID: 36372580 [TBL] [Abstract][Full Text] [Related]
27. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma means no residual tumor: no need to assess "viability". Krasinskas AM Ann Diagn Pathol; 2012 Apr; 16(2):158-9. PubMed ID: 22405469 [No Abstract] [Full Text] [Related]
28. Assessment of Response to Neoadjuvant Therapy Using CT Texture Analysis in Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma. Borhani AA; Dewan R; Furlan A; Seiser N; Zureikat AH; Singhi AD; Boone B; Bahary N; Hogg ME; Lotze M; Zeh HJ; Tublin ME AJR Am J Roentgenol; 2020 Feb; 214(2):362-369. PubMed ID: 31799875 [No Abstract] [Full Text] [Related]
29. Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Borderline Resectable Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgical Resection. Kubo H; Murakami T; Matsuyama R; Yabushita Y; Tsuchiya N; Sawada Y; Homma Y; Kumamoto T; Endo I World J Surg; 2019 Dec; 43(12):3153-3160. PubMed ID: 31549202 [TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline resectable pancreatic cancer: a long-term follow-up study. Endo Y; Kitago M; Aiura K; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Nakano Y; Itano O; Fukada J; Masugi Y; Kitagawa Y World J Surg Oncol; 2019 Aug; 17(1):145. PubMed ID: 31420046 [TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant therapy for non-metastatic pancreatic ductal adenocarcinoma. Winner M; Goff SL; Chabot JA Semin Oncol; 2015 Feb; 42(1):86-97. PubMed ID: 25726054 [TBL] [Abstract][Full Text] [Related]
32. Adjuvant treatment of surgically resectable pancreatic ductal adenocarcinoma. Tesfaye AA; Philip PA Clin Adv Hematol Oncol; 2019 Jan; 17(1):54-63. PubMed ID: 30843899 [TBL] [Abstract][Full Text] [Related]
33. Modified Appleby procedure for borderline resectable/locally advanced distal pancreatic adenocarcinoma: A major procedure for selected patients. Cesaretti M; Abdel-Rehim M; Barbier L; Dokmak S; Hammel P; Sauvanet A J Visc Surg; 2016 Jun; 153(3):173-81. PubMed ID: 26775202 [TBL] [Abstract][Full Text] [Related]
34. Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma. Keane FK; Wo JY; Ferrone CR; Clark JW; Blaszkowsky LS; Allen JN; Kwak EL; Ryan DP; Lillemoe KD; Fernandez-Del Castillo C; Hong TS Am J Clin Oncol; 2018 Jun; 41(6):607-612. PubMed ID: 27740973 [TBL] [Abstract][Full Text] [Related]
35. Objective Assessment of Surgical Restaging after Concurrent Chemoradiation for Locally Advanced Pancreatic Cancer. Paik WH; Lee SH; Kim YT; Park JM; Song BJ; Ryu JK J Korean Med Sci; 2015 Jul; 30(7):917-23. PubMed ID: 26130955 [TBL] [Abstract][Full Text] [Related]
37. Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma. Hashemi-Sadraei N; Gbolahan OB; Salfity H; O'Neil B; House MG; Shahda S Am J Clin Oncol; 2018 Oct; 41(10):982-985. PubMed ID: 28968257 [TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant Therapy: When Should It Be Used for Pancreatic Cancer? Kelly KN; Macedo FI; Merchant NB Adv Surg; 2020 Sep; 54():49-68. PubMed ID: 32713439 [No Abstract] [Full Text] [Related]
39. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy. Barugola G; Partelli S; Crippa S; Capelli P; D'Onofrio M; Pederzoli P; Falconi M Am J Surg; 2012 Feb; 203(2):132-9. PubMed ID: 21824596 [TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant Chemotherapy Enhances Local Postoperative Histopathological Tumour Stage in Borderline Resectable Pancreatic Cancer - A Matched-Pair Analysis. Timmermann L; Rosumeck N; Klein F; Pratschke J; Pelzer U; Bahra M; Malinka T Anticancer Res; 2019 Oct; 39(10):5781-5787. PubMed ID: 31570482 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]